Massachusetts Biotech Presents Catalysts Into 2024
Source: Dr. David Nierengarten
November 9, 2023 (Investorideas.com Newswire) Cambridge, Massachusetts-based iTeos Therapeutics presented multiple upcoming catalysts into 2024 after reporting Q3 results, noted Wedbush analyst Dr. David Nierengarten.
Cambridge, Massachusetts-based iTeos Therapeutics Inc. (ITOS:NASDAQ) reported Q3 2023 financial results and upcoming clinical catalysts, noted Wedbush Securities analyst Dr. David Nierengarten in a November 7 research report.
The key near-term catalysts will be Phase 2 data in 2024 for iTeos' lead asset, TIGIT inhibitor belrestotug, in combination with PD-1 inhibitor dostarlimab from GlaxoSmithKline (GSK) in NSCLC and head and neck squamous cell carcinoma (HNSCC) patients.
Per the analysts, the belrestotug-dostarlimab combo could be differentiated given prior belrestotug monotherapy data and recent positive dostarlimab results versus pembrolizumab.
Beyond NSCLC and HNSCC, belrestotug combination trials are underway in multiple myeloma, plus triplets adding experimental GSK CD96 and PVRIG inhibitors.
For A2A receptor antagonist inupadenant, iTeos is enrolling in a Phase 2 study in lung cancer and plans to start a Phase 1/2 study of inupadenant with pipeline asset EOS-984 in 2024.
The Wedbush analysts highlighted iTeos' "healthy balance sheet" funding operations through 2026 upcoming data readouts for all three clinical programs.
With shares trading below cash value, the firm sees significant upside potential and reiterates an Outperform rating with a US$33 price target.
More Info:
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
